Summary
Background
In COVACTA, a randomised, placebo-controlled trial in patients hospitalised with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but shortened hospital and intensive care unit stay. Longer-term effects of tocilizumab in patients with COVID-19 are unknown. Therefore, the efficacy and safety of tocilizumab in COVID-19 beyond day 28 and its impact on Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) clearance and antibody response in COVACTA were investigated.
Methods
Adults in Europe and North America hospitalised with COVID-19 (N = 452) between April 3, 2020 and May 28, 2020 were randomly assigned (2:1) to double-blind intravenous tocilizumab or placebo and assessed for efficacy and safety through day 60. Assessments included mortality, time to hospital discharge, SARS-CoV-2 viral load in nasopharyngeal swab and serum samples, and neutralising anti-SARS-CoV-2 antibodies in serum. ClinicalTrials.gov registration: NCT04320615.
Findings
By day 60, 24·5% (72/294) of patients in the tocilizumab arm and 25·0% (36/144) in the placebo arm died (weighted difference –0·5% [95% CI –9·1 to 8·0]), and 67·0% (197/294) in the tocilizumab arm and 63·9% (92/144) in the placebo arm were discharged from the hospital. Serious infections occurred in 24·1% (71/295) of patients in the tocilizumab arm and 29·4% (42/143) in the placebo arm. Median time to negative reverse transcriptase–quantitative polymerase chain reaction result in nasopharyngeal/oropharyngeal samples was 15·0 days (95% CI 14·0 to 21·0) in the tocilizumab arm and 21·0 days (95% CI 14·0 to 28·0) in the placebo arm. All tested patients had positive test results for neutralising anti–SARS-CoV-2 antibodies at day 60.
Interpretation
There was no mortality benefit with tocilizumab through day 60. Tocilizumab did not impair viral clearance or host immune response, and no new safety signals were observed. Future investigations may explore potential biomarkers to optimize patient selection for tocilizumab treatment and combination therapy with other treatments.
Funding
F. Hoffmann-La Roche Ltd and the US Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under OT number HHSO100201800036C.
【저자키워드】 Coronavirus disease 2019, randomised controlled trial, Tocilizumab, interleukin-6, severe acute respiratory syndrome coronavirus-2, Viral load, 【초록키워드】 COVID-19, Treatment, SARS-CoV-2, Europe, Mortality, randomised, intensive care, antibody, hospital, Antibody Response, Human, Infection, 28-day mortality, combination therapy, viral clearance, Nasopharyngeal swab, serum, Coronavirus disease-19, Host immune response, anti-SARS-CoV-2 antibody, response, placebo-controlled trial, Patient, Efficacy and safety, Placebo, respiratory, assessment, development, funding, Potential biomarker, double-blind, 95% CI, serum samples, SARS-CoV-2 viral load, hospital discharge, North America, other treatments, positive test result, finding, office, Department, intravenous tocilizumab, patient selection, clearance, authority, Future, Effect, hospitalised, benefit, neutralising, COVACTA, Randomly, polymerase chain, Hoffmann-La Roche, IMPROVE, tested, occurred, died, investigated, assigned, discharged, impair, patients with COVID-19, Secretary, with COVID-19, 【제목키워드】 Antibody Response, viral clearance, Patient, hospitalised, COVACTA, with COVID-19,